The Trump administration, through the Centers for Medicare and Medicaid Services (CMS), is proposing to close a loophole in the Inflation Reduction Act (IRA) that allowed drugmakers to avoid Medicare price negotiations. This proposed rule change aims to codify existing regulations and make them permanent, preventing manufacturers from resetting the negotiation clock by adding new active ingredients to existing drugs. This action is expected to subject blockbuster drugs like Keytruda and Opdivo to price negotiations sooner, even with potential future biosimilar competition. AI
RANK_REASON Policy change impacting major healthcare program and pharmaceutical pricing. [lever_c_demoted from significant: ic=1 ai=0.4]
- Centers for Medicare and Medicaid Services
- Inflation Reduction Act
- Medicare
- Opdivo
- Keytruda
- Trump administration
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
